Revenue decline expected once again for Viatris' Q4 earnings

Viatris (NASDAQ:VTRS) is scheduled to announce Q4 earnings results on Monday, February 27th, before market open.

The consensus EPS Estimate is $0.72 (vs. -$0.22 last year) and the consensus Revenue Estimate is $3.99B (-7.9% Y/Y).

Over the last 1 year, VTRS has beaten EPS estimates 75% of the time and has beaten revenue estimates 50% of the time.

Over the last 3 months, EPS estimates have seen 1 upward revision and 4 downward. Revenue estimates have seen 1 upward revision and 3 downward.

The generic drugmaker in early Nov. 2022 reported mixed Q3 results including a decline in Y/Y revenue. More notably, VTRS also announced a deal to acquire eye disorders-focused company Oyster Point Pharma.

Investors appeared to be positive on the deal, with VTRS stock hitting a multi-month high.

Furthermore, VTRS continued to expand in the field of eye disorders by inking a deal with Ocuphire Pharma (OCUP) to commercialize its lead asset Nyxol once approved.

Another major development for Viatris (VTRS) in Q4 was a court decision win regarding a patent applying to AstraZeneca's (AZN) asthma treatment Symbicort.

In late Nov. 2022, VTRS reportedly decided to withdraw its antimicrobial agent Sulfamylon after 24 years in the market due to difficulties in conducting a confirmatory study.

Read a recent analysis on VTRS by Seeking Alpha contributor Nathan Aisenstadt: What To Expect From Viatris In 2023.